Document is current

Article History

Received: 20 December 2023

Revised: 16 August 2024

Accepted: 23 August 2024

First Online: 5 September 2024

Competing interests

: The authors report the following competing interests: LL, WC, DI, CRK, JJ, TC, RF, TPS, and AG were employees of Myriad Genetics, Inc at the time of the study and received salary and stock options. TPS additionally reports a consulting or advisory role and stock or other ownership interests for Oncodea. AG additionally reports a consulting or advisory role for DermTech. HK reports research funding from Myriad Genetics, Inc. TMM reports consulting or advisory roles for Myriad Genetics, Inc., TERUMO, Blue Earth Diagnostics, Stratify Genomics, Myovant Sciences, Tempus, and Foundation Medicine, as well as institutional research funding from Myriad Genetics, Inc., MDxHealth, and GenomeDx. JH reports consulting or advisory roles for Astellas Pharma, Dendreon, Lilly, Janssen Biotech, LynxDx, Myriad Genetics, Inc., Myovant Sciences, Pfizer, and Promaxo; honoraria, speaker’s bureau, or other compensation from Astellas Pharma, Amgen, Bayer, Blue Earth Diagnostics, Dendreon, Janssen Biotech, Lantheus Medical Imaging, Merck, Myriad Genetics, Inc., Myovant Sciences, Pfizer, Procept BioRobotics, Tolmar, and UroGen Pharma; and institutional research funding from Astellas Pharma, Bayer, Dendreon, Janssen Biotech, Lipella Pharmaceuticals, Merck, miR Scientific, Myriad Genetics, Inc., Myovant Sciences, and Pfizer. RFT reports consulting or advisory roles for Exosome Diagnostics, Myovant Sciences, Nymox, and Novartis; speaker’s bureau fees from Medivation/Astellas, Exosome Diagnostics, and Pfizer; stock or other ownership interests in Compass Therapeutics, GlaxoSmithKline, Nymox, Novartis, Myovant Sciences, and Veru; and institutional research funding from Medivation/Astellas, Janssen Oncology, Bayer, MDxHealth, Genomic Health, Exosome Diagnostics, Advantagene, Merck, POINT Biopharma, Dendreon, and Veru. All other authors have no competing interests to report.

: The analysis described in this manuscript was performed using de-identified data obtained during the course of routine healthcare operations. Individuals provided written informed consent for clinical testing. A Waiver of Informed Consent and Full Waiver of HIPAA Authorization were obtained from Advarra IRB (Reference Number: Pro00047891). The study was performed in accordance with oversight from Advarra IRB; all participating sites were overseen for continued activities.